Core Viewpoint - Hanbang Technology (688755.SH) has made progress in three patent infringement lawsuits against Cytiva, with two patents declared invalid by the National Intellectual Property Administration and one case still under review by the Supreme People's Court [1][2]. Group 1: Patent Litigation Progress - Two of the patents involved in the lawsuits have been declared invalid by the National Intellectual Property Administration, leading to the Supreme People's Court overturning the initial ruling that found Hanbang Technology guilty of infringement [1]. - The lawsuit concerning the "column filling method" is still ongoing, with the first instance ruling in favor of Hanbang Technology, but Cytiva has appealed, and the case is currently under review by the Supreme People's Court [1]. Group 2: Company Overview and Market Position - Hanbang Technology has invested over 108 million yuan in R&D from 2022 to 2024, with R&D personnel accounting for over 20% of its workforce [2]. - The company holds a 39.2% market share in the production-grade small molecule liquid chromatography system, leading the domestic market, while its large molecule chromatography system ranks among the top three, breaking the long-standing monopoly of international giants like Danaher and Sartorius [2]. - Hanbang Technology has developed a comprehensive technical system covering chromatography column technology, system integration, and application solutions, with products used in various applications across over 2,000 domestic and international enterprises [2].
汉邦科技与思拓凡专利纠纷获阶段性进展 自主研发再显优势